Manerix

Moclobemide, the active ingredient in Manerix, is a reversible monoamine oxidase inhibitor presented as a tablet/oral for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Manerix as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manerix (moclobemide) is used within the antidepressant drug class to manage depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves functional capacity in adults.

Moclobemide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dizziness: sensation of light‑headedness. - Dry mouth: reduced salivation. - Constipation: decreased bowel movements.

Serious or Rare Side Effects: - Hypertensive crisis: sudden, severe rise in blood pressure, often after tyramine ingestion. - Serotonin syndrome: agitation, hyperthermia, neuromuscular abnormalities. - Severe liver injury: jaundice, elevated hepatic enzymes. - Agranulocytosis: marked reduction in white blood cells. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating moclobemide therapy, several safety considerations should be observed. - Dietary restriction: avoid tyramine‑rich foods to prevent hypertensive episodes. - Blood pressure monitoring: check regularly, especially after diet changes. - Liver function assessment: evaluate hepatic enzymes prior to and during treatment. - Psychiatric evaluation: screen for history of mania or bipolar disorder. - Discontinuation: taper gradually under medical supervision to reduce withdrawal risk. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Moclobemide can interact with various medicines and substances, requiring careful management.

Major Interactions (Avoid): - Other MAO inhibitors: risk of severe hypertensive or serotonergic events. - Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome. - Meperidine or other opioids: increased risk of hypertensive crisis. - Linezolid: potential for serotonin syndrome. - Tyramine‑rich foods: can trigger hypertensive emergencies.

Moderate Interactions (Monitor Closely): - Sympathomimetic agents (e.g., pseudoephedrine): may elevate blood pressure. - Decongestants (e.g., phenylephrine): monitor cardiovascular response. - Antihypertensive drugs: possible additive hypotensive effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): watch for bleeding risk. - Alcohol: may enhance central nervous system depression.